

Carey Kimmelstiel, Facc, Facp, Fscai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3306392/publications.pdf>

Version: 2024-02-01

59
papers

878
citations

623699

14
h-index

477281

29
g-index

60
all docs

60
docs citations

60
times ranked

1094
citing authors

#	ARTICLE	IF	CITATIONS
1	Unloading the Left Ventricle Before Reperfusion in Patients With Anterior ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation</i> , 2019, 139, 337-346.	1.6	188
2	Randomized, Controlled Evaluation of Short- and Long-Term Benefits of Heart Failure Disease Management Within a Diverse Provider Network. <i>Circulation</i> , 2004, 110, 1450-1455.	1.6	129
3	Role of Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy. <i>Circulation</i> , 2004, 109, 452-456.	1.6	74
4	Bivalirudin Is a Dual Inhibitor of Thrombin and Collagen-Dependent Platelet Activation in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 171-179.	3.9	65
5	Is patent foramen ovale closure effective in reducing migraine symptoms? A controlled study. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 740-746.	1.7	56
6	Survival Following Alcohol Septal Ablation or Septal Myectomy for Patientsâ€With Obstructive Hypertrophicâ€Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1647-1655.	2.8	45
7	Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007673.	3.9	39
8	Noncanonical Matrix Metalloprotease 1â€Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1368-1380.	2.4	38
9	Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials. <i>EuroIntervention</i> , 2012, 8, 187-195.	3.2	35
10	Incidence and clinical outcomes of bleeding complications and acute limb ischemia in STEMI and cardiogenic shock. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1129-1138.	1.7	31
11	Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. <i>Thrombosis Research</i> , 2005, 116, 55-66.	1.7	21
12	Biventricular Circulatory Support Using 2 Axial Flow Catheters for Cardiogenic Shock Without the Need for Surgical Vascular Access. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	20
13	PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2990-3003.	2.4	18
14	Firstâ€inâ€human experience with occlusion of the superior vena cava to reduce cardiac filling pressures in congestive heart failure. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1205-1210.	1.7	16
15	Intermittent Occlusion of the Superior Vena Cava to Improve Hemodynamics in Patients With Acutely Decompensated Heart Failure: The VENUS-HF Early Feasibility Study. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008934.	3.9	16
16	Incidence and clinical outcomes of stroke in ST â€elevation myocardial infarction and cardiogenic shock. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 217-225.	1.7	14
17	Bivalirudin Is Associated With Improved In-Hospital Outcomes Compared With Heparin in Percutaneous Vascular Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e002823.	3.9	11
18	Restrictions on interactions between doctors and industry could ultimately hurt patients. <i>Journal of Vascular Surgery</i> , 2011, 54, 12S-14S.	1.1	9

#	ARTICLE	IF	CITATIONS
19	Comorbidity Burden and Adverse Outcomes After Transcatheter Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2021, 10, e018978.	3.7	8
20	Conversion of Infarction-Associated Atrial Fibrillation by Restoration of Atrial Perfusion. <i>Clinical Cardiology</i> , 2010, 33, E79-81.	1.8	6
21	Deficiency of MMP1a (Matrix Metalloprotease 1a) Collagenase Suppresses Development of Atherosclerosis in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, e265-e279.	2.4	6
22	Stroke due to late device thrombosis following successful percutaneous patent foramen ovale closure. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 498-502.	1.7	5
23	Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel. <i>Thrombosis Research</i> , 2019, 177, 59-69.	1.7	4
24	Reducing arrhythmic complications following alcohol septal ablation—The utility of lower doses of ethanol. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 551-552.	1.7	3
25	Here today, gone tomorrow: Percutaneous closure of atrial septal defects utilizing a bioabsorbable device. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 246-246.	1.7	2
26	Device closure of patent foramen ovale—Do similar devices achieve similar results?. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 715-715.	1.7	2
27	Fixed, high-volume alcohol dose for septal ablation: High risk with no benefit. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 1219-1220.	1.7	2
28	Combined alcohol septal ablation and transcatheter aortic valve replacement: Drunk and playing with fire. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 838-839.	1.7	2
29	Transcatheter Mitral Intervention Relieves Dynamic Outflow Obstruction and Reduces Cardiac Workload in Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009171.	3.9	2
30	Alcohol septal ablation in young children: Addressing large gradients in little people. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 724-725.	1.7	1
31	The effect of differing pharmacologic strategies on infarct size in primary PCI—more confirmatory data for bivalirudin. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 1090-1091.	1.7	1
32	Do We Know, or Do We Believe?. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 130-131.	1.7	1
33	Bivalirudin versus heparin for peripheral vascular intervention: You get what you pay for. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 414-415.	1.7	1
34	Clinical outcomes following implantation of the ION, paclitaxel-eluting platinum chromium coronary stent in routine clinical practice: Results of the ION U.S. post-approval study. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 334-341.	1.7	1
35	Morphine in primary percutaneous coronary intervention—No pain, questionable gain. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 89-90.	1.7	1
36	Transcatheter Tricuspid Valve Intervention in Right Ventricular Dysfunction and Pulmonary Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010482.	3.9	1

#	ARTICLE	IF	CITATIONS
37	Echocardiographic Assessment of Left Ventricular Assist Device Outflow Velocity During Percutaneous Decommissioning. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 1534-1538.	1.3	1
38	Physiologic guidance for percutaneous coronary intervention: State of the evidence. <i>Trends in Cardiovascular Medicine</i> , 2022, . .	4.9	1
39	Percutaneous Decommissioning of a Left Ventricular Assist Device in a Patient With Myocardial Recovery. <i>JACC: Case Reports</i> , 2022, 4, 354-358.	0.6	1
40	Definitive balloon catheter sizing in totally occluded coronary arteries. <i>Catheterization and Cardiovascular Diagnosis</i> , 1992, 26, 159-160.	0.3	0
41	Blood loss following invasive cardiac procedures: Going beyond the CBC. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 387-388.	1.7	0
42	Percutaneous relief of valvular and subvalvular aortic stenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 804-805.	1.7	0
43	Closing one hole leads to another: Delayed aortic perforation following closure of a patent foramen ovale. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 135-136.	1.7	0
44	Competing pharmacological strategies during PCI—analysis of a prematurely terminated trial. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 1010-1011.	1.7	0
45	Alcohol septal ablation via a subendocardial approach: Acute effects in an animal model. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 324-325.	1.7	0
46	Confined distally: A novel method for retrieving a trapped burr. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 565-566.	1.7	0
47	Use of intraprocedural CT imaging to guide alcohol septal ablation. Combining complementary imaging modalities. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 995-996.	1.7	0
48	Retrieval of a trapped burr using the mother and child technique. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 274-274.	1.7	0
49	Aortic valve calcification and the performance of TAVI: Bad actor or part of the scenery?. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 356-357.	1.7	0
50	Low alcohol tolerance—A blessing for septal ablation. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 108-109.	1.7	0
51	Alcohol septal ablation versus surgical myectomy for HCM—the controversy continues. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 278-279.	1.7	0
52	Expanding the armamentarium for effective PFO closure. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 1268-1269.	1.7	0
53	Rotational atherectomy: A persistently relevant niche device. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 632-633.	1.7	0
54	Thrombin inhibition during PCI in heart failure patients. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 374-375.	1.7	0

#	ARTICLE	IF	CITATIONS
55	Ablation or surgery for medically refractory <scp>HCM</scp>. Updating an imperfect dataset. Catheterization and Cardiovascular Interventions, 2016, 88, 116-117.	1.7	0
56	Heparin or bivalirudin for non-â€primary <scp>PCI</scp>: Beware of neat and simple answersâ€ . Catheterization and Cardiovascular Interventions, 2017, 90, 378-379.	1.7	0
57	Real life experience with bioresorbable-â€polymer everolimus-â€eluting stents. Is this an answer in search of a question?. Catheterization and Cardiovascular Interventions, 2017, 90, 888-889.	1.7	0
58	Striking a balance between quality and cost in PCI. Catheterization and Cardiovascular Interventions, 2017, 89, 1213-1214.	1.7	0
59	Stretching and cutting after drilling. Vessel preparation following rotational atherectomy. Catheterization and Cardiovascular Interventions, 2022, 99, 1750-1751.	1.7	0